Cyclacel’s CYC065 CDK Inhibitor Demonstrates Synergy With Venetoclax By Dual Targeting Of Chronic Lymphocytic Leukemia

by NASDAQ Market News April 17, 2018

NASDAQ Market News
Click here to email author

Shire plc : FDA APPROVES VONVENDI® FOR PERIOPERATIVE MANAGEMENT OF BLEEDING IN ADULT PATIENTS WITH VON WILLEBRAND DISEASE

Cesca Therapeutics Announces First Evaluation Agreement With a Leading U.S. Academic Research Institution for X-Series™ Products That Provide Automated, Closed System Cellular Processing

Ads